The Remaking Of India
A Covid-19 test. (representative image)
Snapshot
There is much to learn from the Indian experience with the virus.
Any government must have a body that is paranoid and focuses on what could go wrong.
There needs to be a healthy and constructive balance between the optimists and the prudent ones inside the government.
I just happened to come across the article in
Financial Times (FT) by Ramachandra Guha (âThe unmaking of Indiaâ, 30
April 2021). The comments in the article by Guha reflect the widespread anger and resentment at the deaths and the personal sufferings that many have experienced directly or indirectly.
Final results will be out in June
It added that safety and efficacy results from the final analysis of Covaxin will be available in June, and the final report will be submitted to a peer-reviewed publication. Based on the achievement of the success criteria, placebo recipients have now become eligible to receive two doses of Covaxin, it said.
Phase 3 clinical trials of Covaxin saw participation of 25,800 volunteers between 18-98 years of age. Ten per cent of the total volunteers were aged more than 60. Efficacy against SARS-Cov-2 has been established. Covaxin has demonstrated an excellent safety record in human clinical trials and in usage under emergency use. Covaxin is now a global innovator vaccine derived from R&D in India, Bharat Biotech Chairman and Managing Director Krishna Ella said.
Bharat Biotech Says Covaxin Shows 78% Efficacy Against Mild To Severe COVID-19 Bharat Biotech Says Covaxin Shows 78% Efficacy Against Mild To Severe COVID-19 Efficacy against SARS-Cov-2 has been established. Covaxin has demonstrated an excellent safety record in human clinical trials and in usage under emergency use. Covaxin is now a global innovator vaccine derived from R&D in India, Bharat Biotech Chairman and Managing Director Krishna Ella said.
Bharat Biotech said Covaxin showed efficacy of 78% against mild, moderate and severe cases
New Delhi:
Bharat Biotech on Wednesday said its coronavirus vaccine Covaxin has shown efficacy of 78 per cent against mild, moderate and severe cases of COVID-19, as per Phase III interim analysis results.
Share this article
SELBYVILLE, Del., April 21, 2021 /PRNewswire/ According to the latest report Microcatheter Market by Product (Delivery Microcatheters, Diagnostic Microcatheters, Aspiration Microcatheters, Steerable Microcatheters), Design (Single Lumen Microcatheters, Dual Lumen Microcatheters), Application (Cardiovascular, Neurovascular, Peripheral Vascular, Oncology), Regional Outlook, Price Trends, Competitive Market Share & Forecast 2027 , by Global Market Insights Inc., the market valuation of microcatheters will cross $1.3 billion by 2027.
Major microcatheter market players include Terumo Medical Corporation, Stryker, Medtronic, Boston Scientific Corporation, Teleflex Inc., Penumbra Inc., and Merit Medical System.
The growing focus of key industry players in introducing innovative and technologically advanced product offerings is playing a vital role in the market growth. The surging number of microcatheter-related studies and research is another factor fostering t